Jiayun Liu

Title: Innovations by Jiayun Liu in Non-Viral Gene Therapy

Introduction

Jiayun Liu is a notable inventor based in Wellesley, MA, recognized for his contributions to the fields of molecular biology and gene therapy. With a total of two patents to his name, Liu has made significant strides in the development of nucleic acid molecules aimed at improving therapeutic interventions.

Latest Patents

Liu's latest patents focus on nucleic acid molecules that facilitate non-viral gene therapy. One of his inventions involves nucleic acid molecules that comprise a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. This target sequence can encode a microRNA (miRNA) or a therapeutic protein. Notably, the therapeutic proteins include clotting factors, growth factors, hormones, cytokines, antibodies, or fragments thereof. These innovations hold promise for treating various metabolic disorders of the liver by administering the specified nucleic acid molecules. Another patent similarly outlines the use of nucleic acid molecules with an ITR of a non-adeno-associated virus (AAV) to devise treatments for bleeding disorders like hemophilia.

Career Highlights

Jiayun Liu is currently associated with Bioverativ Therapeutics Inc., a company devoted to advancing therapies for hemophilia and other blood disorders. His research and development work in therapeutic proteins exemplifies a strong commitment to improving patient outcomes through innovative technology.

Collaborations

In his professional journey, Liu collaborates with esteemed colleagues such as Alexey Seregin and Tongyao Liu. Their collective efforts contribute to the advancement of research in gene therapy and enhance the potential for impactful medical treatments.

Conclusion

Jiayun Liu's work in nucleic acid molecules signifies a pivotal advancement in non-viral gene therapy. His innovative patents and collaborations with fellow researchers emphasize the potential for new treatment methods that could significantly improve the lives of individuals affected by genetic disorders. As he continues his work at Bioverativ Therapeutics Inc., the impact of his contributions remains vital to future medical breakthroughs.